Advertisement
Advertisement
RMD
ResMed Inc.
230.80
USDSponsored
-1.61
-0.69%
Mar 13, 15:59 UTC -4
Closed
After-Market
232.97
+2.17
+0.94%
RMD Earnings Reports
Positive Surprise Ratio
RMD beat 27 of 40 last estimates.
68%
Next Report
Date of Next Report
Apr 21, 2026
Estimate for Q3 26 (Revenue/ EPS)
$1.44B
/$2.83
Implied change from Q2 26 (Revenue/ EPS)
+0.99%
/+0.71%
Implied change from Q3 25 (Revenue/ EPS)
+11.24%
/+19.41%
ResMed Inc. earnings per share and revenue
On Jan 29, 2026, RMD reported earnings of 2.81 USD per share (EPS) for Q2 26, beating the estimate of 2.75 USD, resulting in a 2.15% surprise. Revenue reached 1.42 billion, compared to an expected 1.41 billion, with a 0.89% difference. The market reacted with a +0.27% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 17 analysts forecast an EPS of 2.83 USD, with revenue projected to reach 1.44 billion USD, implying an increase of 0.71% EPS, and increase of 0.99% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
BillionToOne, Inc. Class A Common Stock
Report Date
Mar 04, 2026 For Q4 25
Estimate
$0.08
Actual
$0.11
Surprise
+27.02%
Capricor Therapeutics Inc
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.55
Actual
-$0.62
Surprise
-12.56%
Brainsway Ltd. - ADR
Report Date
Mar 11, 2026 For Q4 25
Estimate
$0.13
Actual
$0.14
Surprise
+6.63%
Sundial Growers Inc. Common Shares
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.01
Actual
$0.04
Surprise
+499.62%
Apyx Medical Corporation Common Stock
Report Date
Mar 10, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.03
Surprise
+48.63%
MacroGenics, Inc.
Report Date
Mar 09, 2026 For Q4 25
Estimate
-$0.29
Actual
-$0.23
Surprise
+22.40%
Biote Corp. Class A Common Stock
Report Date
Mar 11, 2026 For Q4 25
Estimate
$0.05
Actual
$0.06
Surprise
+17.65%
Exagen Inc. Common Stock
Report Date
Mar 10, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.20
Surprise
-4.22%
Nephros Inc.
Report Date
Mar 12, 2026 For Q4 25
Estimate
$0.01
Actual
$0.01
Surprise
-1.96%
Myomo Inc.
Report Date
Mar 09, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.08
Surprise
+2.19%
FAQ
What were ResMed Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, ResMed Inc. reported EPS of $2.81, beating estimates by 2.15%, and revenue of $1.42B, 0.89% above expectations.
How did the market react to ResMed Inc.'s Q2 2026 earnings?
The stock price moved up 0.27%, changed from $257.61 before the earnings release to $258.31 the day after.
When is ResMed Inc. expected to report next?
The next earning report is scheduled for Apr 21, 2026.
What are the forecasts for ResMed Inc.'s next earnings report?
Based on 17
analysts, ResMed Inc. is expected to report EPS of $2.83 and revenue of $1.44B for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement